Login to Your Account

GTx, Merck in $500M Deal For Muscle Loss Drugs

By Donna Young

Wednesday, November 7, 2007
GTx Inc. has partnered with Merck and Co. Inc. in a deal worth at least $500 million to develop and commercialize selective androgen receptor modulators (SARMs), a new class of drugs that target musculoskeletal conditions, such as age-related muscle loss. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription